{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:48:03Z","timestamp":1789044483575,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T00:00:00Z","timestamp":1413590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00228-014-1773-z","type":"journal-article","created":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T02:00:20Z","timestamp":1413511220000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy"],"prefix":"10.1007","volume":"71","author":[{"given":"Sachiyo","family":"Hashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,18]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"YT Ng","year":"2007","unstructured":"Ng YT, Collins SD (2007) Clobazam. Neurotherapeutics 4:138\u2013144","journal-title":"Neurotherapeutics"},{"key":"1773_CR2","first-page":"763","volume-title":"Antiepileptic drugs","author":"SD Shorvon","year":"1995","unstructured":"Shorvon SD (1995) Benzodiazepines: clobazam. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press Ltd, New York, pp 763\u2013777","edition":"4"},{"key":"1773_CR3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJM199606133342407","volume":"334","author":"MA Dichter","year":"1996","unstructured":"Dichter MA, Brodie MJ (1996) New antiepileptic drugs. N Engl J Med 334:1583\u20131590","journal-title":"N Engl J Med"},{"key":"1773_CR4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J Leon de","year":"2013","unstructured":"de Leon J, Spina E, Diaz FJ (2013) Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 35:30\u201347","journal-title":"Ther Drug Monit"},{"key":"1773_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1528-1157.1991.tb04670.x","volume":"32","author":"Canadian Clobazam Cooperative Group","year":"1991","unstructured":"Canadian Clobazam Cooperative Group (1991) Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32:407\u2013416","journal-title":"Epilepsia"},{"key":"1773_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1157.1986.tb05730.x","volume":"27","author":"MM Robertson","year":"1986","unstructured":"Robertson MM (1986) Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam. Epilepsia 27:27\u201341","journal-title":"Epilepsia"},{"key":"1773_CR7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/archneur.1986.00520080064023","volume":"43","author":"D Schmidt","year":"1986","unstructured":"Schmidt D, Rohde M, Wolf P, Roeder-Wanner U (1986) Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol 43:824\u2013826","journal-title":"Arch Neurol"},{"key":"1773_CR8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G (2004) In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 32:1279\u20131286","journal-title":"Drug Metab Dispos"},{"key":"1773_CR9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","volume":"11","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lane EA, Guyot M, Brachet-Liermain A, Cenraud B, Loiseau P (1983) Analysis of parent drug-metabolic relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 11:286\u2013292","journal-title":"Drug Metab Dispos"},{"key":"1773_CR10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2125.1984.tb02558.x","volume":"18","author":"S Jawad","year":"1984","unstructured":"Jawad S, Richens A, Oxley J (1984) Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol 18:873\u2013877","journal-title":"Br J Clin Pharmacol"},{"key":"1773_CR11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","volume":"14","author":"S Sennoue","year":"1992","unstructured":"Sennoue S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J (1992) Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 14:269\u2013274","journal-title":"Ther Drug Monit"},{"key":"1773_CR12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/088307389701200311","volume":"12","author":"JG Theis","year":"1997","unstructured":"Theis JG, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P (1997) Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 12:208\u2013213","journal-title":"J Child Neurol"},{"key":"1773_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00007691-200202000-00016","volume":"24","author":"H Hachad","year":"2002","unstructured":"Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24:91\u2013103","journal-title":"Ther Drug Monit"},{"key":"1773_CR14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","volume":"14","author":"MS Benedetti","year":"2000","unstructured":"Benedetti MS (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14:301\u2013319","journal-title":"Fundam Clin Pharmacol"},{"key":"1773_CR15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1248\/bpb.19.444","volume":"19","author":"A Odani","year":"1996","unstructured":"Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, Yasuhara M, Hattori H, Frusho K, Inui K (1996) Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 19:444\u2013448","journal-title":"Biol Pharm Bull"},{"key":"1773_CR16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM Morais de","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"1773_CR17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007691-200212000-00009","volume":"24","author":"M Contin","year":"2002","unstructured":"Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A (2002) Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 24:737\u2013741","journal-title":"Ther Drug Monit"},{"key":"1773_CR18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","volume":"6","author":"K Kosaki","year":"2004","unstructured":"Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Tahakashi T (2004) A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 6:530\u2013534","journal-title":"Brain Dev"},{"key":"1773_CR19","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/bi00173a017","volume":"33","author":"JA Goldstein","year":"1994","unstructured":"Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4\u2032-hydroxylase in humans. Biochemistry 33:1743\u20131752","journal-title":"Biochemistry"},{"key":"1773_CR20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00008571-199704000-00003","volume":"7","author":"K Inoue","year":"1997","unstructured":"Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103\u2013113","journal-title":"Pharmacogenetics"},{"key":"1773_CR21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2007.05.025","volume":"263","author":"M Kinoshita","year":"2007","unstructured":"Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H (2007) Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 263:44\u201348","journal-title":"J Neurol Sci"},{"key":"1773_CR22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1773_CR23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554\u2013563","journal-title":"Ann Pharmacother"},{"key":"1773_CR24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.108.025833","volume":"37","author":"K Hosohata","year":"2009","unstructured":"Hosohata K, Masuda S, Katsura T, Takada Y, Kaido T, Ogura Y, Oike F, Egawa H, Uemoto S, Inui K (2009) Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 37:821\u2013826","journal-title":"Drug Metab Dispos"},{"key":"1773_CR25","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","volume":"48","author":"RH Schaik van","year":"2002","unstructured":"van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668\u20131671","journal-title":"Clin Chem"},{"key":"1773_CR26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Mosh\u00e9 SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51:676\u2013685","journal-title":"Epilepsia"},{"key":"1773_CR27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389\u2013399","journal-title":"Epilepsia"},{"key":"1773_CR28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489\u2013501","journal-title":"Epilepsia"},{"key":"1773_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.1979.tb05920.x","volume":"7","author":"S Fielding","year":"1979","unstructured":"Fielding S, Hoffmann I (1979) Pharmacology of anti-anxiety drugs with special reference to clobazam. Br J Clin Pharmacol 7:7\u201315","journal-title":"Br J Clin Pharmacol"},{"key":"1773_CR30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/14622416.9.5.527","volume":"9","author":"T Seo","year":"2008","unstructured":"Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K (2008) Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics 9:527\u2013537","journal-title":"Pharmacogenomics"},{"key":"1773_CR31","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/bmj.286.6373.1246","volume":"286","author":"JW Allen","year":"1983","unstructured":"Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS (1983) Clobazam as adjunctive treatment in refractory epilepsy. Br Med J 286:1246\u20131247","journal-title":"Br Med J"},{"key":"1773_CR32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","volume":"42","author":"HM Neels","year":"2004","unstructured":"Neels HM, Sierens AC, Naelaerts K, Scharp\u00e9 SL, Hatfield GM, Lambert WE (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42:1228\u20131255","journal-title":"Clin Chem Lab Med"},{"key":"1773_CR33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276","journal-title":"Epilepsia"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1773-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1773-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:37:36Z","timestamp":1746423456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1773-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1773-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,18]]}}}